HIGH

Nilotinib Capsules Recall Expands in 2026 Over Stability Issue (Cipla USA)

Cipla USA recalls 271 cartons of Nilotinib 150 mg capsules nationwide after stability tests show out-of-spec results. The issue affects description and appearance by visual inspection. Stop using and contact Cipla USA or a clinician for guidance.

Quick Facts at a Glance

Recall Date
February 18, 2026
Hazard Level
HIGH
Brands
Nilotinib, Cipla USA
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Cipla USA, Inc. or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Nilotinib is a prescription tyrosine kinase inhibitor used to treat certain leukemias. This recall involves 150 mg capsules distributed in the United States.

Why This Is Dangerous

Stability-related failures can affect potency and appearance, potentially impacting drug efficacy and safety.

Industry Context

This recall is not described as part of a broader industry pattern in the notice.

Real-World Impact

Patients relying on Nilotinib for cancer treatment may be affected. There is no reported injury in the notice, but the medication could be subpotent or misrepresented until resolved.

Practical Guidance

How to identify if yours is affected

  1. Verify packaging: outer carton 112 capsules (4 packs of 28)
  2. Check NDC codes: 69097-031-74 (outer), 69097-031-56 (inner), 69097-031-17 (foil)
  3. Check Lot numbers: 5GJ0220, 5GJ0221, 5GJ0222
  4. Check expiry: Exp 04/30/2027
  5. Stop using if affected and contact Cipla USA or your clinician
  6. Keep recall notice and packaging for records

Where to find product info

Cipla USA contact details at 10 Independence Boulevard, Suite 300, Warren, NJ 07059. FDA recall page: enforce_rpt-Product-Tabs.cfm?recall_number=D-0381-2026

What timeline to expect

Recall is active; no refund details provided. Follow Cipla guidance and clinician instructions. Replacement or compensation not specified.

If the manufacturer is unresponsive

  • Escalate to Cipla USA customer service
  • Consult your pharmacist or physician
  • Document all communications and seek FDA assistance if needed

How to prevent similar issues

  • Verify NDC and lot numbers before dispensing or dispensing anew
  • Only purchase from licensed pharmacies
  • Be aware of Rx-only recalls and return policies for prescription meds

Documentation advice

Keep recall notice, packaging, and any medical records related to the product for future reference

Product Details

Nilotinib capsules, 150 mg, manufactured by Cipla Ltd. in Verna, Goa, India, for Cipla USA, Warren, NJ. Recall covers 271 cartons nationwide. Outer carton: 112 capsules (4 packs of 28). Inner carton: 28 capsules (4 blisters of 7). NDCs: 69097-031-74 (outer), 69097-031-56 (inner), 69097-031-17 (foil). Lot numbers: 5GJ0220, 5GJ0221, 5GJ0222. Expiration: 04/30/2027. Class III recall.

Key Facts

  • 271 cartons recalled
  • Outer carton: 112 capsules (4 packs of 28)
  • Inner carton: 28 capsules (4 blisters of 7)
  • NDCs: 69097-031-74; 69097-031-56; 69097-031-17
  • Lot numbers: 5GJ0220, 5GJ0221, 5GJ0222
  • Exp 04/30/2027

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
6/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Details

Model Numbers
Lot #: 5GJ0220
Lot #: 5GJ0221
Lot #: 5GJ0222
Exp 04/30/2027
UPC Codes
69097-030
69097-031
69097-032
+10 more
Affected States
ALL
Report Date
March 11, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more